Prednisolone

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Prednisolone

Examples of brand names: Decortin H [DE]

ATC code: H02AB06

Main use (for orientation): Inflammatory diseases

Documented research summary

CBD enhanced prednisolone cytotoxicity in a canine lymphoma cell line (preclinical proof of concept). No verified clinical prednisolone–cannabinoid pharmacokinetics or confirmation of benefit.

Uncertainties and limitations

Oral 5 mg tablet; CYP3A hypothesis not directly investigated clinically with CBD.

Shared enzymes must not be equated with clinical evidence of an interaction; CBD/THC findings cannot be extrapolated to other cannabinoids.

Separately recorded findings

1 separately recorded finding. Each statement applies to its documented study context.

CBD – laboratory and animal studies

Finding ID: B0254

Type of result: Preclinical in vitro

Observation: CBD synergistically enhanced prednisolone effects in the cell assay used.

Mechanism: Combined cytotoxicity in a canine lymphoma cell line

Study type: Canine B-NHL1771, MTT/Chou–Talalay

Context studied: Each CHOP component combined separately; AEA/WIN also tested, but outside the scope of 28.

Clinical interpretation: Experimental, not a clinical drug–drug interaction

Limitations and uncertainties: No human pharmacokinetics/efficacy/safety; do not infer prednisone data.

Original sources for this finding: Cytotoxicity of Cannabinoids in Combination with Traditional Lymphoma Chemotherapeutic Drugs Against Non-Hodgkin's Lymphoma. [BMED41595541]

References and access status

[BAWEB_PRED] Prednisolone Tablets BP5mg – Summary of Product Characteristics

Original source / bibliographic reference

Authors: Strides Pharma UK Ltd

Year: 2026

Source type: Official UK product information via emc

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[BMED41595541] Cytotoxicity of Cannabinoids in Combination with Traditional Lymphoma Chemotherapeutic Drugs Against Non-Hodgkin's Lymphoma.

Original source / bibliographic reference

Authors: Omer S, Mansour M, Pondugula SR, Dhanasekaran M, Matz B, Khan O, Boothe D.

Year: 2025

Source type: Publication; title and abstract reviewed

DOI: 10.3390/biomedicines14010003

PMID: 41595541

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – archived text

DOI – publisher access (access restrictions may apply)

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility